Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Lia Gore

Concepts (523)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
35
2026
299
6.460
Why?
Antineoplastic Combined Chemotherapy Protocols
43
2026
1996
3.440
Why?
Antibodies, Bispecific
13
2025
70
3.220
Why?
Neoplasms
43
2026
2944
2.930
Why?
Antineoplastic Agents
35
2024
2218
2.820
Why?
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
11
2025
91
2.700
Why?
Induction Chemotherapy
5
2026
87
1.780
Why?
Maximum Tolerated Dose
21
2023
216
1.350
Why?
Medical Oncology
5
2023
344
1.250
Why?
Child
77
2026
22638
1.240
Why?
Hematopoietic Stem Cell Transplantation
9
2025
700
1.170
Why?
Recurrence
22
2026
1125
1.120
Why?
Pyridines
8
2025
606
1.070
Why?
Oligopeptides
4
2026
264
1.070
Why?
Neoplasm Recurrence, Local
13
2024
1156
1.060
Why?
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
2022
25
0.980
Why?
Lymphoma, Non-Hodgkin
2
2022
124
0.960
Why?
Antibodies, Monoclonal
11
2018
1511
0.930
Why?
Antineoplastic Agents, Immunological
4
2024
200
0.930
Why?
Lymphoma, B-Cell
6
2023
149
0.920
Why?
Immunotherapy
6
2023
669
0.860
Why?
Child, Preschool
42
2026
11888
0.800
Why?
Treatment Outcome
36
2026
11744
0.780
Why?
Leukemia, Myeloid, Acute
9
2022
700
0.780
Why?
Humans
138
2026
145625
0.770
Why?
Hodgkin Disease
3
2025
173
0.770
Why?
Clinical Trials as Topic
8
2024
1062
0.770
Why?
Leukemia
6
2021
246
0.740
Why?
Azacitidine
4
2024
168
0.730
Why?
Etoposide
7
2022
169
0.730
Why?
Adolescent
49
2026
22451
0.730
Why?
Benzamides
4
2021
226
0.720
Why?
Antigens, CD19
7
2026
137
0.690
Why?
Dose-Response Relationship, Drug
19
2025
2018
0.650
Why?
Lymphoma, Large-Cell, Anaplastic
2
2018
23
0.630
Why?
para-Aminobenzoates
1
2019
8
0.610
Why?
T-Lymphocytes
5
2026
2007
0.610
Why?
Quinazolines
3
2010
267
0.590
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
2018
128
0.590
Why?
Deoxycytidine
4
2011
219
0.590
Why?
Proto-Oncogene Proteins c-mdm2
1
2019
66
0.590
Why?
Rare Diseases
2
2017
115
0.580
Why?
Prodrugs
1
2019
54
0.580
Why?
Infant
28
2026
10093
0.580
Why?
Histone Deacetylase Inhibitors
5
2021
218
0.580
Why?
Protein Kinase Inhibitors
10
2024
982
0.570
Why?
Brain Stem Neoplasms
3
2017
86
0.570
Why?
Myeloid-Lymphoid Leukemia Protein
4
2024
72
0.570
Why?
Pyrrolidines
1
2019
126
0.560
Why?
Immunotherapy, Adoptive
7
2026
356
0.560
Why?
Male
80
2026
73014
0.560
Why?
Dasatinib
2
2018
58
0.550
Why?
DNA Methylation
3
2024
721
0.550
Why?
Female
79
2026
79080
0.540
Why?
Immunoconjugates
2
2025
138
0.540
Why?
Astrocytoma
3
2017
128
0.530
Why?
Piperidines
2
2010
223
0.520
Why?
Poverty
1
2021
530
0.490
Why?
Glioma
5
2022
425
0.470
Why?
Antibodies, Monoclonal, Humanized
11
2021
992
0.460
Why?
Young Adult
34
2026
14240
0.450
Why?
Chemoradiotherapy
2
2017
238
0.450
Why?
Administration, Oral
9
2019
867
0.450
Why?
Sirolimus
2
2016
282
0.440
Why?
Biomedical Research
3
2017
724
0.440
Why?
Sulfonamides
5
2020
592
0.430
Why?
Glycine
3
2025
184
0.430
Why?
Camptothecin
3
2017
139
0.410
Why?
Adult
50
2025
40821
0.410
Why?
Follow-Up Studies
16
2025
5397
0.410
Why?
Lymphoma
2
2023
251
0.410
Why?
Nausea
3
2009
111
0.410
Why?
Drug Administration Schedule
10
2017
782
0.390
Why?
Fluorouracil
4
2012
231
0.380
Why?
Receptor, IGF Type 1
2
2010
64
0.380
Why?
Arsenicals
1
2013
28
0.370
Why?
Oxides
1
2013
47
0.370
Why?
Histone-Lysine N-Methyltransferase
3
2024
141
0.370
Why?
Prognosis
14
2024
4331
0.360
Why?
Molecular Targeted Therapy
5
2021
446
0.360
Why?
DNA Damage
5
2023
437
0.360
Why?
Disease-Free Survival
8
2024
777
0.360
Why?
Purine-Nucleoside Phosphorylase
2
2010
6
0.350
Why?
TOR Serine-Threonine Kinases
6
2024
454
0.340
Why?
Remission Induction
4
2026
308
0.330
Why?
Vomiting
2
2009
131
0.330
Why?
Neuroblastoma
2
2023
177
0.330
Why?
Topoisomerase II Inhibitors
1
2010
24
0.320
Why?
Biomarkers, Tumor
7
2021
1334
0.310
Why?
Doxorubicin
5
2025
414
0.310
Why?
Asparaginase
3
2026
34
0.310
Why?
Papillomavirus Infections
2
2024
345
0.300
Why?
Urinary Bladder Neoplasms
2
2023
257
0.300
Why?
Infusions, Intravenous
4
2019
429
0.300
Why?
Cyclophosphamide
3
2022
275
0.290
Why?
Aged
28
2025
26251
0.290
Why?
Leukemia, B-Cell
2
2021
12
0.290
Why?
Everolimus
2
2020
112
0.290
Why?
Carboplatin
2
2009
168
0.280
Why?
Pediatrics
3
2008
1122
0.280
Why?
Arabinonucleosides
2
2022
8
0.280
Why?
Clinical Trials, Phase I as Topic
2
2018
49
0.280
Why?
Boronic Acids
1
2008
37
0.270
Why?
Morpholines
1
2009
130
0.270
Why?
Purine Nucleosides
1
2007
4
0.270
Why?
Farnesyltranstransferase
1
2007
21
0.270
Why?
Burkitt Lymphoma
2
2023
61
0.270
Why?
Graft vs Leukemia Effect
1
2007
12
0.270
Why?
Drug Resistance, Neoplasm
7
2021
889
0.260
Why?
Pyrazines
1
2008
94
0.260
Why?
Middle Aged
29
2025
36359
0.260
Why?
Epigenesis, Genetic
3
2024
705
0.260
Why?
Isocitrate Dehydrogenase
2
2025
71
0.250
Why?
Survival Rate
7
2024
2078
0.250
Why?
Pyrimidinones
1
2007
124
0.250
Why?
Combined Modality Therapy
6
2021
1269
0.240
Why?
Myelodysplastic Syndromes
2
2020
170
0.240
Why?
Cytarabine
4
2020
66
0.230
Why?
Ethics, Medical
1
2006
90
0.230
Why?
Angiogenesis Inhibitors
4
2014
238
0.230
Why?
Vincristine
3
2021
148
0.230
Why?
Polyethylene Glycols
4
2020
649
0.230
Why?
Cisplatin
1
2007
346
0.230
Why?
Philadelphia Chromosome
2
2024
18
0.230
Why?
Kaplan-Meier Estimate
5
2024
959
0.220
Why?
Chondrosarcoma
1
2025
17
0.220
Why?
Glycogen Synthase Kinase 3 beta
2
2024
74
0.220
Why?
Craniopharyngioma
2
2017
77
0.220
Why?
Methotrexate
2
2020
234
0.220
Why?
Pyrazoles
1
2008
516
0.210
Why?
Receptors, Antigen, T-Cell
2
2026
676
0.210
Why?
Neoplasm, Residual
3
2022
143
0.210
Why?
Neuropilin-1
2
2014
8
0.210
Why?
Prospective Studies
10
2024
8087
0.200
Why?
Anesthetics, Intravenous
1
2024
67
0.200
Why?
Oropharyngeal Neoplasms
1
2024
56
0.200
Why?
Propofol
1
2024
86
0.190
Why?
Spinal Neoplasms
1
2003
36
0.190
Why?
fms-Like Tyrosine Kinase 3
2
2021
51
0.190
Why?
Drug Discovery
2
2015
153
0.190
Why?
Plant Nectar
1
2022
8
0.180
Why?
Nucleosides
1
2022
25
0.180
Why?
Bone Neoplasms
1
2025
271
0.180
Why?
Drug Design
2
2017
179
0.180
Why?
Cystectomy
1
2022
44
0.180
Why?
Drug Delivery Systems
3
2015
377
0.180
Why?
Osteosarcoma
1
2003
100
0.180
Why?
Neutropenia
4
2017
153
0.180
Why?
Aged, 80 and over
10
2019
8351
0.180
Why?
Proto-Oncogene Proteins c-akt
1
2024
438
0.170
Why?
Capecitabine
3
2011
56
0.170
Why?
Glycolipids
1
2021
53
0.170
Why?
Artificial Gene Fusion
1
2000
3
0.170
Why?
Tobacco Products
1
2022
90
0.160
Why?
Proto-Oncogenes
1
2000
27
0.160
Why?
Area Under Curve
4
2009
333
0.160
Why?
Hematology
1
2001
21
0.160
Why?
Carbazoles
1
2021
53
0.160
Why?
Carcinoma, Renal Cell
2
2022
229
0.160
Why?
Vaping
1
2022
81
0.160
Why?
Nervous System Neoplasms
1
2020
3
0.160
Why?
Bone Marrow
2
2019
308
0.160
Why?
Electronic Nicotine Delivery Systems
1
2022
112
0.160
Why?
Papillomavirus Vaccines
1
2024
296
0.160
Why?
Lower Urinary Tract Symptoms
1
2021
62
0.160
Why?
Acute Disease
4
2023
1033
0.160
Why?
Weight Reduction Programs
1
2022
140
0.150
Why?
Hospice Care
1
2023
230
0.150
Why?
Mindfulness
1
2022
133
0.150
Why?
DNA-Binding Proteins
3
2002
1467
0.150
Why?
United States
10
2024
16041
0.150
Why?
Cell Lineage
1
2021
375
0.150
Why?
Growth Differentiation Factor 15
1
2019
44
0.150
Why?
Bridged Bicyclo Compounds, Heterocyclic
2
2020
291
0.150
Why?
Cytokines
3
2017
2079
0.150
Why?
Cohort Studies
9
2022
6045
0.140
Why?
Proteasome Inhibitors
1
2018
42
0.140
Why?
Head and Neck Neoplasms
1
2024
563
0.140
Why?
Cytochrome P-450 CYP3A Inhibitors
1
2018
18
0.140
Why?
Survivors
1
2022
521
0.140
Why?
Transcription Factors
3
2002
1728
0.140
Why?
Transplantation, Homologous
2
2018
415
0.140
Why?
Mutation
4
2025
4082
0.140
Why?
Fetal Blood
1
2000
325
0.140
Why?
Cytochrome P-450 CYP3A
1
2018
93
0.130
Why?
Cholangiocarcinoma
1
2019
110
0.130
Why?
Imatinib Mesylate
1
2018
77
0.130
Why?
Melanoma
3
2017
764
0.130
Why?
Single-Blind Method
2
2016
312
0.130
Why?
Daunorubicin
1
2017
25
0.130
Why?
Cyst Fluid
1
2017
20
0.130
Why?
Bile Duct Neoplasms
1
2019
132
0.130
Why?
Kidney Neoplasms
1
2022
417
0.130
Why?
United States Food and Drug Administration
3
2023
207
0.130
Why?
Ipilimumab
1
2017
44
0.130
Why?
Tetrahydronaphthalenes
1
2017
34
0.130
Why?
Antimetabolites, Antineoplastic
2
2024
108
0.130
Why?
Valine
1
2017
84
0.130
Why?
Heterocyclic Compounds
1
2017
23
0.130
Why?
Cord Blood Stem Cell Transplantation
2
2010
103
0.130
Why?
Dexamethasone
3
2020
368
0.130
Why?
Amyloid Precursor Protein Secretases
1
2017
80
0.120
Why?
Neoplasm Proteins
3
2009
443
0.120
Why?
Carbolines
1
2017
35
0.120
Why?
Heterocyclic Compounds, 4 or More Rings
1
2017
24
0.120
Why?
Stem Cell Transplantation
1
2018
189
0.120
Why?
Fellowships and Scholarships
1
2001
353
0.120
Why?
Age Factors
4
2018
3321
0.120
Why?
Pancreatitis
1
2017
146
0.120
Why?
Anemia, Sickle Cell
1
2000
322
0.120
Why?
Weight Loss
1
2022
857
0.120
Why?
Central Nervous System Neoplasms
2
2009
177
0.110
Why?
Brain Neoplasms
2
2020
1324
0.110
Why?
Proto-Oncogene Proteins
4
2014
615
0.110
Why?
Cancer Survivors
1
2021
347
0.110
Why?
Vascular Endothelial Growth Factor A
5
2010
543
0.110
Why?
Bacterial Infections
1
2017
246
0.110
Why?
Tumor Suppressor Protein p53
1
2019
530
0.110
Why?
Pituitary Neoplasms
1
2017
190
0.110
Why?
EGF Family of Proteins
1
2015
17
0.110
Why?
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)
1
2015
16
0.110
Why?
Receptor, EphA2
1
2015
17
0.110
Why?
Parents
1
2024
1393
0.110
Why?
Paclitaxel
2
2014
258
0.110
Why?
Receptor, ErbB-3
1
2015
48
0.110
Why?
Bortezomib
2
2020
54
0.110
Why?
RNA, Messenger
5
2017
2783
0.110
Why?
src-Family Kinases
1
2015
93
0.110
Why?
Leukemia, Monocytic, Acute
1
2014
3
0.100
Why?
Sarcoma, Myeloid
1
2014
6
0.100
Why?
Cetuximab
2
2017
110
0.100
Why?
Calcineurin Inhibitors
1
2014
67
0.100
Why?
Fusion Proteins, bcr-abl
1
2014
68
0.100
Why?
Disease Progression
4
2021
2857
0.100
Why?
Gram-Positive Bacterial Infections
1
2014
72
0.100
Why?
Apoptosis
4
2010
2436
0.100
Why?
Drug Synergism
2
2014
353
0.100
Why?
ErbB Receptors
2
2015
636
0.100
Why?
Neoplasm Staging
5
2017
1486
0.100
Why?
Diphenylamine
1
2013
7
0.100
Why?
Tissue Distribution
2
2013
334
0.100
Why?
Sulfones
1
2014
127
0.100
Why?
Survival Analysis
1
2016
1372
0.100
Why?
Models, Biological
3
2025
1758
0.090
Why?
Protein-Tyrosine Kinases
2
2023
429
0.090
Why?
Lymphohistiocytosis, Hemophagocytic
1
2013
33
0.090
Why?
Immune System Diseases
1
2013
42
0.090
Why?
Research Design
3
2024
1139
0.090
Why?
Promoter Regions, Genetic
1
2017
1236
0.090
Why?
Bone Marrow Transplantation
1
2014
298
0.090
Why?
Adenine Nucleotides
1
2012
21
0.090
Why?
T-Lymphocytes, Cytotoxic
1
2013
180
0.090
Why?
Mitogen-Activated Protein Kinase 1
1
2013
169
0.090
Why?
Health Services Accessibility
1
2021
1101
0.090
Why?
Early Detection of Cancer
1
2017
501
0.090
Why?
Macrophage Activation
1
2013
182
0.090
Why?
Enzyme Inhibitors
3
2014
820
0.090
Why?
Neoplasm Grading
1
2013
313
0.090
Why?
Randomized Controlled Trials as Topic
3
2024
1754
0.090
Why?
Dioxoles
1
2011
9
0.090
Why?
Tetrahydroisoquinolines
1
2011
8
0.090
Why?
Pilot Projects
3
2022
1878
0.090
Why?
Fatigue
3
2009
362
0.080
Why?
HL-60 Cells
1
2010
29
0.080
Why?
Gene Expression Profiling
4
2017
1790
0.080
Why?
Tumor Cells, Cultured
2
2010
878
0.080
Why?
Inhibitory Concentration 50
1
2010
90
0.080
Why?
Cysteine Proteinase Inhibitors
1
2010
48
0.080
Why?
TNF-Related Apoptosis-Inducing Ligand
1
2010
54
0.080
Why?
Skin Neoplasms
1
2017
805
0.080
Why?
Neoplastic Stem Cells
1
2014
402
0.080
Why?
Glucuronidase
2
2008
27
0.080
Why?
Estrenes
1
2010
12
0.080
Why?
Graft vs Host Disease
2
2010
280
0.080
Why?
Anemia
2
2009
189
0.080
Why?
Hepatocyte Growth Factor
1
2010
33
0.080
Why?
Acute Kidney Injury
1
2017
861
0.080
Why?
Oligosaccharides
2
2008
61
0.070
Why?
Vascular Endothelial Growth Factor Receptor-2
1
2010
86
0.070
Why?
Early Termination of Clinical Trials
2
2021
18
0.070
Why?
Salvage Therapy
2
2021
163
0.070
Why?
Risk Factors
3
2024
10840
0.070
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
1
2009
31
0.070
Why?
Poly(ADP-ribose) Polymerases
1
2009
88
0.070
Why?
Intercellular Signaling Peptides and Proteins
2
2008
372
0.070
Why?
Hematologic Neoplasms
1
2011
169
0.070
Why?
Ondansetron
1
2009
19
0.070
Why?
Hydrocortisone
2
2022
303
0.070
Why?
Metabolic Clearance Rate
1
2009
115
0.070
Why?
Celecoxib
1
2008
42
0.070
Why?
Placebos
1
2009
190
0.070
Why?
Sulindac
1
2008
16
0.070
Why?
Angiogenic Proteins
1
2008
15
0.070
Why?
Hepatoblastoma
1
2009
52
0.070
Why?
Chemistry, Pharmaceutical
1
2008
112
0.070
Why?
Plateletpheresis
1
2008
28
0.070
Why?
MAP Kinase Kinase 2
1
2008
28
0.070
Why?
Mice
7
2023
18266
0.070
Why?
Neovascularization, Pathologic
1
2010
285
0.070
Why?
Prednisone
2
2020
229
0.070
Why?
Dibenzocycloheptenes
1
2007
5
0.070
Why?
Lymphoma, Large B-Cell, Diffuse
1
2010
195
0.070
Why?
MAP Kinase Kinase 1
1
2008
70
0.070
Why?
Cell Proliferation
3
2010
2497
0.070
Why?
Quality of Life
2
2015
3187
0.070
Why?
Animals
9
2023
38030
0.070
Why?
HSP40 Heat-Shock Proteins
1
2007
26
0.070
Why?
Rhabdoid Tumor
1
2009
99
0.070
Why?
Carcinogens
1
2008
111
0.070
Why?
Cell Cycle
1
2010
595
0.060
Why?
Cell Survival
1
2010
1102
0.060
Why?
DNA Modification Methylases
1
2007
19
0.060
Why?
Feasibility Studies
2
2022
1125
0.060
Why?
DNA Repair Enzymes
1
2007
29
0.060
Why?
Food
1
2008
149
0.060
Why?
Incidence
2
2024
2910
0.060
Why?
Dacarbazine
1
2007
98
0.060
Why?
Antineoplastic Agents, Alkylating
1
2007
76
0.060
Why?
Lactams, Macrocyclic
1
2007
51
0.060
Why?
Benzoquinones
1
2007
46
0.060
Why?
Benzimidazoles
1
2008
189
0.060
Why?
MAP Kinase Signaling System
1
2008
306
0.060
Why?
Xenograft Model Antitumor Assays
1
2010
928
0.060
Why?
Fasting
1
2008
280
0.060
Why?
Leukemia, T-Cell
1
2006
5
0.060
Why?
Thrombocytopenia
1
2008
205
0.060
Why?
Retreatment
2
2016
79
0.060
Why?
Drug-Related Side Effects and Adverse Reactions
1
2009
266
0.060
Why?
Microarray Analysis
2
2017
117
0.060
Why?
Flow Cytometry
5
2014
1160
0.060
Why?
Estradiol
1
2010
517
0.060
Why?
Lymphoma, T-Cell
1
2006
31
0.060
Why?
Risk
1
2008
917
0.060
Why?
Genotype
3
2016
1866
0.060
Why?
Receptors, Interleukin-6
2
2017
49
0.060
Why?
Body Surface Area
1
2025
33
0.050
Why?
Vinblastine
1
2025
75
0.050
Why?
Histocompatibility Testing
2
2005
122
0.050
Why?
Retrospective Studies
6
2023
17291
0.050
Why?
Tumor Suppressor Proteins
1
2007
314
0.050
Why?
Time Factors
4
2019
7079
0.050
Why?
Receptor Protein-Tyrosine Kinases
1
2006
226
0.050
Why?
DNA Primers
2
2006
487
0.050
Why?
Cell Cycle Proteins
2
2014
629
0.050
Why?
Florida
1
2024
117
0.050
Why?
Blood Preservation
1
2008
346
0.050
Why?
Double-Blind Method
1
2009
2064
0.050
Why?
Gene Rearrangement
1
2024
155
0.050
Why?
Caregivers
2
2023
1079
0.050
Why?
Glioblastoma
1
2007
349
0.050
Why?
Survival
1
2003
38
0.050
Why?
Stereotaxic Techniques
1
2003
42
0.050
Why?
BRCA2 Protein
1
2023
68
0.050
Why?
BRCA1 Protein
1
2023
83
0.050
Why?
Thoracic Vertebrae
1
2003
90
0.050
Why?
Oncogene Proteins, Fusion
1
2024
212
0.050
Why?
Tissue Donors
1
2005
398
0.050
Why?
Biometry
1
2022
66
0.050
Why?
Morbidity
1
2003
317
0.040
Why?
Germ Cells
1
2022
66
0.040
Why?
Clinical Trials, Phase II as Topic
1
2022
74
0.040
Why?
Gangliosides
1
2021
23
0.040
Why?
Base Sequence
2
2006
2119
0.040
Why?
Cytoreduction Surgical Procedures
1
2022
69
0.040
Why?
Embryo, Mammalian
1
2002
230
0.040
Why?
Antibiotics, Antineoplastic
2
2016
140
0.040
Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2023
137
0.040
Why?
Smokers
1
2022
139
0.040
Why?
Mitogen-Activated Protein Kinases
1
2022
288
0.040
Why?
Consolidation Chemotherapy
1
2021
11
0.040
Why?
Hematopoiesis
1
2002
195
0.040
Why?
Furans
1
2021
26
0.040
Why?
Central Nervous System
1
2023
278
0.040
Why?
Nephrectomy
1
2022
169
0.040
Why?
Puerto Rico
1
2001
64
0.040
Why?
Aftercare
1
2022
221
0.040
Why?
Piperazines
1
2023
367
0.040
Why?
Bevacizumab
2
2014
167
0.040
Why?
Gene Expression
2
2016
1461
0.040
Why?
Lung Neoplasms
1
2014
2674
0.040
Why?
Seizures
1
2024
489
0.040
Why?
Mitoxantrone
1
2020
14
0.040
Why?
Injections, Spinal
1
2020
120
0.040
Why?
Antigens
1
2001
350
0.040
Why?
Certification
1
2001
117
0.040
Why?
Biomarkers
2
2023
4329
0.040
Why?
Cost of Illness
1
2021
322
0.040
Why?
Mercaptopurine
1
2018
15
0.040
Why?
Case-Control Studies
2
2018
3633
0.040
Why?
Urinary Bladder
1
2021
194
0.040
Why?
Behavior Therapy
1
2022
290
0.040
Why?
Signal Transduction
3
2024
5234
0.040
Why?
Microsomes, Liver
1
2018
85
0.040
Why?
Midazolam
1
2018
69
0.030
Why?
Primary Cell Culture
1
2018
172
0.030
Why?
Sepsis
1
2024
668
0.030
Why?
Fibroblast Growth Factor 2
2
2008
93
0.030
Why?
Hepatocytes
1
2018
224
0.030
Why?
Drug Interactions
1
2018
403
0.030
Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
1
2017
56
0.030
Why?
Sample Size
1
2017
123
0.030
Why?
Partial Thromboplastin Time
2
2008
53
0.030
Why?
Benzylamines
1
2017
44
0.030
Why?
Chronic Disease
1
2023
1824
0.030
Why?
Eligibility Determination
1
2017
72
0.030
Why?
Risk Assessment
1
2006
3678
0.030
Why?
Membrane Proteins
1
2023
1130
0.030
Why?
Receptors, CXCR4
1
2017
90
0.030
Why?
Guidelines as Topic
1
2018
267
0.030
Why?
Bendamustine Hydrochloride
1
2016
18
0.030
Why?
Program Evaluation
1
2001
945
0.030
Why?
Oligonucleotide Array Sequence Analysis
2
2009
751
0.030
Why?
Benzothiazoles
1
2016
39
0.030
Why?
Quinoxalines
1
2016
63
0.030
Why?
Patient Discharge
1
2022
991
0.030
Why?
Education, Medical, Graduate
1
2001
566
0.030
Why?
Cognition
1
2024
1286
0.030
Why?
Amphiregulin
1
2015
27
0.030
Why?
Rituximab
1
2016
208
0.030
Why?
Phenylurea Compounds
1
2016
122
0.030
Why?
Cells, Cultured
2
2018
4112
0.030
Why?
Multimodal Imaging
1
2016
138
0.030
Why?
Palliative Care
1
2023
1032
0.030
Why?
Immunohistochemistry
2
2009
1709
0.020
Why?
Thiazoles
1
2014
139
0.020
Why?
Phosphorylation
2
2008
1717
0.020
Why?
Magnetic Resonance Imaging
2
2020
3917
0.020
Why?
Patient Selection
1
2017
720
0.020
Why?
Cyclosporine
1
2014
256
0.020
Why?
Cell Line, Tumor
2
2014
3538
0.020
Why?
Infant, Newborn
2
2015
6449
0.020
Why?
Cell Differentiation
3
2009
1979
0.020
Why?
Tomography, X-Ray Computed
1
2003
2766
0.020
Why?
Organoplatinum Compounds
1
2012
65
0.020
Why?
Drug Monitoring
1
2016
399
0.020
Why?
Leucovorin
1
2012
98
0.020
Why?
Cross-Sectional Studies
1
2024
5875
0.020
Why?
Syndrome
1
2013
377
0.020
Why?
Phenotype
1
2000
3186
0.020
Why?
Up-Regulation
1
2015
840
0.020
Why?
Safety
1
2014
346
0.020
Why?
Research
1
2015
421
0.020
Why?
Gene Expression Regulation, Neoplastic
1
2017
1429
0.020
Why?
Phosphotransferases
1
2010
26
0.020
Why?
Myeloablative Agonists
1
2010
23
0.020
Why?
Pyrimidines
1
2014
530
0.020
Why?
Transcription, Genetic
1
2017
1429
0.020
Why?
Surveys and Questionnaires
1
2023
6050
0.020
Why?
Neuroectodermal Tumors, Primitive
1
2009
10
0.020
Why?
Choroid Plexus Neoplasms
1
2009
8
0.020
Why?
Papilloma
1
2009
17
0.020
Why?
RNA, Neoplasm
1
2009
76
0.020
Why?
Severity of Illness Index
1
2017
2910
0.020
Why?
Mice, Inbred C57BL
2
2014
6021
0.020
Why?
Alopecia
1
2009
33
0.020
Why?
Vascular Endothelial Growth Factor Receptor-1
1
2010
74
0.020
Why?
Poly (ADP-Ribose) Polymerase-1
1
2009
55
0.020
Why?
Comparative Genomic Hybridization
1
2009
28
0.020
Why?
Demography
1
2010
274
0.020
Why?
Transplantation Conditioning
1
2010
191
0.020
Why?
alpha-Fetoproteins
1
2009
42
0.020
Why?
Species Specificity
1
2010
542
0.020
Why?
Maximum Allowable Concentration
1
2008
15
0.020
Why?
Dogs
1
2010
516
0.020
Why?
Platelet-Derived Growth Factor
1
2008
85
0.020
Why?
Floxuridine
1
2008
5
0.020
Why?
Obesity
1
2022
3123
0.020
Why?
Protein Kinase C beta
1
2008
21
0.020
Why?
Platelet Factor 4
1
2008
36
0.020
Why?
Glycogen Synthase Kinase 3
1
2008
83
0.020
Why?
Reference Standards
1
2008
176
0.020
Why?
Ki-67 Antigen
1
2008
119
0.020
Why?
Taxoids
1
2008
115
0.020
Why?
DNA Repair
1
2009
254
0.020
Why?
Extracellular Signal-Regulated MAP Kinases
1
2008
173
0.020
Why?
ras Proteins
1
2008
148
0.020
Why?
DNA Mutational Analysis
1
2008
409
0.020
Why?
Proto-Oncogene Proteins p21(ras)
1
2008
250
0.020
Why?
Pharmacogenetics
1
2008
176
0.020
Why?
Thymidine
1
2006
57
0.020
Why?
Carcinoid Tumor
1
2006
21
0.020
Why?
DNA, Neoplasm
1
2007
160
0.020
Why?
Leiomyosarcoma
1
2006
30
0.020
Why?
Protein Kinase C
1
2008
250
0.020
Why?
Genome, Human
1
2009
425
0.020
Why?
Heparin
1
2008
246
0.010
Why?
Down Syndrome
1
2013
529
0.010
Why?
Gene Silencing
1
2007
200
0.010
Why?
c-Mer Tyrosine Kinase
1
2006
36
0.010
Why?
Chromatography, High Pressure Liquid
1
2008
588
0.010
Why?
Proto-Oncogene Proteins B-raf
1
2008
230
0.010
Why?
Drug Screening Assays, Antitumor
1
2006
194
0.010
Why?
Treatment Failure
1
2007
358
0.010
Why?
Gastrointestinal Diseases
1
2008
220
0.010
Why?
Transforming Growth Factor beta
1
2008
466
0.010
Why?
Fibroblast Growth Factors
1
2006
187
0.010
Why?
Antibody Formation
1
2006
290
0.010
Why?
Leukocytes, Mononuclear
1
2008
585
0.010
Why?
Monocytes
1
2008
538
0.010
Why?
Tandem Mass Spectrometry
1
2008
574
0.010
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2006
973
0.010
Why?
Indoles
1
2008
509
0.010
Why?
Yolk Sac
1
2002
5
0.010
Why?
Core Binding Factor Alpha 2 Subunit
1
2002
32
0.010
Why?
Erythropoiesis
1
2002
57
0.010
Why?
E2F2 Transcription Factor
1
2001
14
0.010
Why?
Multivariate Analysis
1
2005
1531
0.010
Why?
Bromodeoxyuridine
1
2001
74
0.010
Why?
Ribonucleases
1
2001
49
0.010
Why?
E2F Transcription Factors
1
2001
65
0.010
Why?
E2F1 Transcription Factor
1
2001
68
0.010
Why?
Sensitivity and Specificity
1
2006
1992
0.010
Why?
Rats
1
2010
5574
0.010
Why?
Mice, Transgenic
1
2006
2131
0.010
Why?
Cell Division
1
2001
735
0.010
Why?
Lymphocytes
1
2001
379
0.010
Why?
Spleen
1
2001
503
0.010
Why?
Blotting, Western
1
2001
1176
0.010
Why?
Lymph Nodes
1
2001
511
0.010
Why?
Hematopoietic Stem Cells
1
2002
432
0.010
Why?
Colorectal Neoplasms
1
2006
870
0.010
Why?
Gene Expression Regulation, Developmental
1
2002
899
0.010
Why?
Mice, Knockout
1
2001
3121
0.010
Why?
Gore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)